Literature DB >> 16483154

[Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma].

Qing Yao1, Xiao-song He, Jian-min Zhang, Jie He.   

Abstract

OBJECTIVE: To investigate promotor hypermethylation of the CpG islands of E-Cadherin, p16 and estrogen receptor (ER) in prostate carcinoma and explore whether such methylation might play a role in the tumorigenesis and malignant progression of prostate carcinoma and their significance in the diagnosis, prognosis and treatment.
METHODS: Thirteen specimens of benign prostatic hypertrophy (BPH), 10 specimens of high grade prostate intraepithelial neoplasia (HGPIN) and 20 specimens of prostate carcinoma (with follow-up records) were collected from the patients who underwent radical prostatectomy or transurethral resection. Methylation-specific PCR (MSP) was used to detect the promoter hypermethylation of E-Cadherin, p16 and ER genes.
RESULTS: Hypermethylation percentages in prostate carcinoma were: E-Cadherin, 30%; p16, 25%; and ER, 65%. Almost all nonmalignant tissues (BPH and HG-PIN) lacked methylation of any genes.
CONCLUSION: Detecting promotor hypermethylation of E-Cadherin, p16 and ER may be helpful to differentiate nonmalignant lesions from prostate carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483154

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  6 in total

Review 1.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

2.  Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.

Authors:  Zheng Chang; Hongbing Zhou; Yi Liu
Journal:  Tumour Biol       Date:  2014-07-24

3.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

4.  Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer.

Authors:  Ahmad Ameri; Asdollah Alidoosti; Seyed Yousef Hosseini; Mohammad Parvin; Mohammad Hasan Emranpour; Farnaz Taslimi; Eisa Salehi; Pedram Fadavip
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

5.  Frequent DNA Hypermethylation at the RASSF1A and APC Gene Loci in Prostate Cancer Patients of Pakistani Origin.

Authors:  Ahmed Yaqinuddin; Sohail A Qureshi; Shahid Pervez; Mohammed Umair Bashir; Ressam Nazir; Farhat Abbas
Journal:  ISRN Urol       Date:  2013-01-30

6.  Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).

Authors:  Zipei Cao; Lijuan Wei; Weizhi Zhu; Xuping Yao
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.